ClinicalTrials.gg
CompletedNCT05168644Updated Feb 2, 2022

Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects

A Phase 1 interventional study of Niclosamide Inhalation Powder and Placebo in Healthy, sponsored by TFF Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-02.

Sponsored by TFF Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of Niclosamide Inhalation Powder versus placebo (SAD part) and escalating multiple doses of Niclosamide Inhalation Powder versus placebo (MAD part). SAD part will be initiated first and includes a sentinel design. MAD part will not utilize a sentinel design unless the data monitoring committee requests the addition of sentinels. The MAD part will be initiated once the lowest doses from SAD part are deemed safe.

Read the detailed description

This is a Phase 1, randomized, 2 part double-blind, placebo-controlled trial to evaluate the safety and PK profiles of Niclosamide Inhalation Powder in a SAD/MAD study design.

Part A is a double-blinded, placebo-controlled, randomized, dose- ranging single dose study evaluating four different dose levels.

On Day 1 of each group, two selected subjects (sentinel subjects) will receive either Niclosamide Inhalation Powder or a matching placebo. Blood samples and safety measurements including Adverse Events (AEs) will be collected over 24 hour period following the drug administration. The safety results to be evaluated include AEs, concomitant medications, out of specification clinical laboratory results, vital signs, Electrocardiograms (ECGs), visual examinations, pulmonary function tests, pulse oximetry results and any new findings on physical examinations. If the administration is safe as deemed by Principal Investigator \& Medical Monitor, the remaining six subjects will be dosed (5 dosed with Niclosamide Inhalation Powder and 1 dosed with matching placebo), with identical safety and PK procedures performed after minimum of 2 days interval. A minimum of 3 days will separate each dose escalation, with the remaining dose groups dosed in a sentinel fashion.

Part B is a double-blinded, placebo-controlled, randomized, dose- ranging multi-dose study evaluating two different dose levels. Dose level 1 of Part B can begin once the data monitoring committee reviews the safety data and indicates safety is present. Niclosamide Inhalation Powder will be administered twice daily (BID) × 9 doses. Blood samples for safety and PK will be collected throughout confinement, which is 7 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

TFF Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Agree to use acceptable or is not able to bear children.
  2. (BMI) within ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2 at Screening (body weight of at least 50.0 kg and no more than120 kg at Screening).
  3. Non-smoker or ex-smoker (stopped using nicotine products for at least 12 months prior to the first study drug administration and throughout the study).
  4. Have no diseases, including asthma, captured in the medical history or on the physical examination, visual examination, clinical laboratory assessments, and/or .
  5. A forced expiratory volume during the first second () ≥ 80% at Screening and Check-in.

Exclusion criteria

Exclusion Criteria

  1. Female who is lactating, is pregnant or planning to become pregnant according to the pregnancy test at Screening or prior to the first study drug administration.
  2. Is mentally or legally incapacitated or unable to provide .
  3. History or presence of alcoholism or drug abuse within the past 2 years prior to the first study drug administration.
  4. History or presence of or idiosyncratic reaction to niclosamide or any portion of the placebo.
  5. Has had surgery or any medical condition within 6 months prior to first study drug administration which may affect the absorption, distribution, metabolism, or elimination of the study drug, in the opinion of the PI or designee.
  6. Use of albuterol or a similar bronchodilator.
  7. Immunization with a COVID-19 vaccine in the 14 days prior to the first study drug administration.
  8. Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason.
  9. History or allergy of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
  10. Unable to refrain from or anticipates the use of:

    1. Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study.
    2. Seasonal use of albuterol or other similar inhalers throughout study participation, beginning 14 days prior to the first dosing or 5 half-lives, whichever is longer.
  11. Use of St. John's wort in the 28 days prior to the first study drug administration.
  12. Positive Screening results for tuberculosis, Ag/Ab combo, surface antigen or virus tests, or a positive test for alcohol, cotinine, and/or drugs of abuse.
  13. Participation in another clinical study within 30 days prior to the first study drug administration. The 30-day window will be derived from the date of the last study drug administration.
  14. Had a treatment with another drug within 5 times the elimination half-life, if known (eg, a marketed product) or within 30 days (if the elimination half-life is unknown) prior to the first study drug administration.
  15. Donation of plasma in the 14 days prior to the first study drug administration.
  16. Donation or loss of 500 mL or more of blood in the 56 days prior to the first study drug administration.
  17. Demonstrates an inability to operate the inhalation device after training.
  18. History or presence of any drug or food allergies.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Drug: Niclosamide Inhalation Powder

    PART A (SAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 0.5 mg, Cohort 2: 2 mg, Cohort 3: 6 mg. PART B (MAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. MAD subjects will receive Niclosamide Inhalation Powder BID for a total of 9 doses. Subjects in Cohort 4 will receive 3 mg BID, Cohort 5: 6 mg BID.

    Drug: Niclosamide Inhalation Powder

  • Placebo comparator
    Drug: Placebo

    PART A (SAD): Placebo will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. SAD subjects (Part A) will receive a single dose of Placebo. PART B (MAD): Placebo inhalation powder will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period. MAD subjects (Part B) will receive Placebo inhalation powder BID for a total of 9 doses.

    Drug: Placebo

Interventions

  • DrugNiclosamide Inhalation Powder

    Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.

  • DrugPlacebo

    Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.

06

What researchers measure

Primary outcomes

  1. Number of participants who experience Adverse Events (AEs), Serious Adverse Events (SAEs) and withdrawals due to AEs

    Number of AEs, SAEs, and discontinuation due to AEs

    Time frame: Baseline through study completion, up to 43 days

  2. Number of participants who experience vital sign abnormalities

    Number of participants with potentially clinically significant vital sign values

    Time frame: Baseline through study completion, up to 43 days

  3. Number of participants who experience pulse oximetry abnormalities

    Number of participants with potentially clinically significant pulse oximetry values

    Time frame: Baseline through study completion, up to 43 days

  4. Mean change from baseline in forced expiratory volume (FEV1)

    Spirometry used to measure FEV1 lung function

    Time frame: Baseline through study completion, up to 43 days

  5. Mean change from baseline in forced vital capacity (FVC)

    Spirometry used to measure FVC lung function

    Time frame: Baseline through study completion, up to 43 days

  6. Mean change from baseline in FEV1/FVC ratio

    Spirometry used to measure FEV1 and FVC lung function

    Time frame: Baseline through study completion, up to 43 days

  7. Mean change from baseline in QTcF changes via ECG

    Number of participants with potentially clinically significant ECG values

    Time frame: Baseline through study completion, up to 43 days

  8. Number of participants who experience physical examination abnormalities

    Number of participants with potentially clinically significant physical examination findings

    Time frame: Baseline through study completion, up to 43 days

  9. Number of participants who experience laboratory test abnormalities

    Number of participants with potentially clinically significant laboratory test results

    Time frame: Baseline through study completion, up to 43 days

Secondary outcomes

  1. PK of Niclosamide in plasma: Area under the plasma-concentration time curve (AUC)

    Blood samples will be collected for plasma analysis

    Time frame: Baseline through study completion, up to 43 days

  2. PK of Niclosamide in plasma: Area under the concentration time curve, from time 0 to the last observed non-zero concentration (AUC0-tlast)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  3. PK of Niclosamide in plasma: Maximum observed concentration (Cmax)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  4. PK of Niclosamide in plasma: Trough or minimum concentration (Ctrough)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  5. PK of Niclosamide in plasma: Concentration at the end of the dosing interval (Ct)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  6. PK of Niclosamide in plasma: Time to maximal observed concentration (tmax)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  7. PK of Niclosamide in plasma: Accumulation ratio (comparing Day 5 Cmax to Day 1 Cmax)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  8. PK of Niclosamide in plasma: Accumulation ratio (comparing Day 5 AUCtau to Day 1 AUC0-12)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  9. PK of Niclosamide in plasma: Area under the plasma-concentration time curve over the first 12 hours after dosing (AUC0-12)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  10. PK of Niclosamide in plasma: Area under the concentration time curve from time 0 extrapolated to infinity (AUC∞)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  11. PK of Niclosamide in plasma: Termination elimination half-life (t½)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  12. PK of Niclosamide in plasma: Apparent total body clearance (CL/F)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

  13. PK of Niclosamide in plasma: Apparent volume of distribution during the terminal elimination phase (Vz/F)

    Blood samples will be collected for analysis

    Time frame: Baseline through study completion, up to 43 days

07

Study locations

1 site
  • Altasciences
    Mount Royal, Quebec, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Dec 23, 2021
StartActual
Nov 14, 2021
Primary completionActual
Jan 26, 2022
CompletionActual
Jan 26, 2022
Last update
Feb 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05168644
Lead sponsor
TFF Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 23, 2021
Start date
Nov 14, 2021
Primary completion
Jan 26, 2022
Completion
Jan 26, 2022
Last update
Feb 2, 2022

Study contacts

Dale Christensen, PhD
study director · TFF Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion